Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Cocaine-Related Disorders · Cocaine Dependence · DRUG

BRIGHT MINDS BIOSCIENCES

BRIGHT MINDS BIOSCIENCES INC.

BRIGHT MINDS BIOSCIENCES clinical programs — 1063 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
19 Vestry St, New York, NY 10013, US HQ
12 Employees
Public company Type
DRUG · NYSE Ticker
Company details
Status
Public
HQ
19 Vestry St, New York, NY 10013, US
Employees
12
Programs
1063
Drugs
444
Patents
57
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Clinical Programs

BRIGHT MINDS BIOSCIENCES projects

1,063 ClinicalTrials.gov programs sponsored by BRIGHT MINDS BIOSCIENCES.

BRIGHT MINDS BIOSCIENCES has 1,063 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

1,063 programs

Clinical programs

Page 6 of 23

  1. Divalproex Sodium (Depakote)

    BRIGHT MINDS BIOSCIENCES INC.

    Mood Disorders

    phase 2 small molecule completed

    1 trial

  2. Docetaxel

    BRIGHT MINDS BIOSCIENCES INC.

    Prostatic Neoplasms

    phase 2 small molecule completed

    1 trial

  3. Double Trouble in Recovery

    BRIGHT MINDS BIOSCIENCES INC.

    Dual Diagnosis

    phase 2 other completed

    1 trial

  4. Doxazosin

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence

    phase 2 small molecule completed

    2 trials

  5. Doxazosin 4mg/day

    BRIGHT MINDS BIOSCIENCES INC.

    Smoking

    phase 2 small molecule completed

    1 trial

  6. Doxazosin extended release

    BRIGHT MINDS BIOSCIENCES INC.

    Methamphetamine or Cocaine Dependence

    phase 2 small molecule completed

    1 trial

  7. Dronabinol

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis Use Disorder

    phase 2 small molecule active

    1 trial

  8. Dronabinol

    BRIGHT MINDS BIOSCIENCES INC.

    Marijuana Dependence

    phase 2 small molecule terminated

    2 trials

  9. Dronabinol 120mg/day

    BRIGHT MINDS BIOSCIENCES INC.

    Marijuana Smoking

    phase 2 small molecule completed

    1 trial

  10. Dronabinol 30mg/day

    BRIGHT MINDS BIOSCIENCES INC.

    Marijuana Abuse

    phase 2 small molecule completed

    1 trial

  11. Dynorphin 1 - 13

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid-Related Disorders

    phase 2 small molecule completed

    1 trial

  12. E-cigarettes

    BRIGHT MINDS BIOSCIENCES INC.

    Nicotine Dependence

    phase 2 other completed

    1 trial

  13. EMB-001

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Use Disorder

    phase 2 small molecule completed

    2 trials

  14. EVP-6124

    BRIGHT MINDS BIOSCIENCES INC.

    Nicotine Dependence

    phase 2 small molecule terminated

    1 trial

  15. Enzalutamide

    BRIGHT MINDS BIOSCIENCES INC.

    Prostate Cancer Metastatic

    phase 2 small molecule completed

    1 trial

  16. Everolimus

    BRIGHT MINDS BIOSCIENCES INC.

    Epilepsy

    phase 2 small molecule active

    1 trial

  17. Evolution: Young Women Taking Charge and Growing Stronger

    BRIGHT MINDS BIOSCIENCES INC.

    HIV

    phase 2 other completed

    1 trial

  18. Extended-Release Naltrexone

    BRIGHT MINDS BIOSCIENCES INC.

    HIV

    phase 2 small molecule completed

    1 trial

  19. FINGER 2.0 multidomain lifestyle-based intervention

    BRIGHT MINDS BIOSCIENCES INC.

    Cognitive Decline

    phase 2 other active

    1 trial

  20. Family Therapy based on Structural Family Therapy

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Use Disorders

    phase 2 other completed

    1 trial

  21. Flumazenil

    BRIGHT MINDS BIOSCIENCES INC.

    Substance-Related Disorders

    phase 2 small molecule completed

    1 trial

  22. Fluorodopa F 18

    BRIGHT MINDS BIOSCIENCES INC.

    Malignant Brain Neoplasm

    phase 2 small molecule active

    1 trial

  23. Fluoxetine

    BRIGHT MINDS BIOSCIENCES INC.

    Depressive Disorder, Major

    phase 2 small molecule completed

    1 trial

  24. Flupenthixol

    BRIGHT MINDS BIOSCIENCES INC.

    Substance-Related Disorders

    phase 2 small molecule completed

    1 trial

  25. Flupenthixol

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 2 small molecule completed

    1 trial

  26. G-202

    BRIGHT MINDS BIOSCIENCES INC.

    Glioblastoma Multiforme

    phase 2 small molecule completed

    1 trial

  27. GDCRI/ACM/PG/PhD/10/2013-14

    BRIGHT MINDS BIOSCIENCES INC.

    Chronic Periodontitis

    phase 2 small molecule completed

    1 trial

  28. GSK598809

    BRIGHT MINDS BIOSCIENCES INC.

    Nicotine Dependence

    phase 2 small molecule completed

    1 trial

  29. GTS-21

    BRIGHT MINDS BIOSCIENCES INC.

    Tobacco Use Disorder

    phase 2 small molecule terminated

    1 trial

  30. GW468816

    BRIGHT MINDS BIOSCIENCES INC.

    Nicotine Dependence

    phase 2 small molecule completed

    1 trial

  31. Gabapentin

    BRIGHT MINDS BIOSCIENCES INC.

    Pain

    phase 2 small molecule active

    1 trial

  32. Gabapentin

    BRIGHT MINDS BIOSCIENCES INC.

    Benzodiazepine Dependence

    phase 2 small molecule completed

    1 trial

  33. Galantamine

    BRIGHT MINDS BIOSCIENCES INC.

    Tobacco Use Disorder

    phase 2 small molecule completed

    1 trial

  34. Galantamine

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence

    phase 2 small molecule completed

    1 trial

  35. Gamma hydroxybutyric

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid-Related Disorders

    phase 2 small molecule terminated

    1 trial

  36. Gates MRI-TBD06-201

    BRIGHT MINDS BIOSCIENCES INC.

    Pulmonary Tuberculosis

    phase 2 small molecule terminated

    1 trial

  37. Gemcitabine

    BRIGHT MINDS BIOSCIENCES INC.

    Treatment Refusal

    phase 2 small molecule active

    1 trial

  38. Gemcitabine/Cisplatin

    BRIGHT MINDS BIOSCIENCES INC.

    Upper Tract Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  39. Gepirone

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 2 small molecule completed

    1 trial

  40. Guanfacine

    BRIGHT MINDS BIOSCIENCES INC.

    Smoking

    phase 2 small molecule completed

    2 trials

  41. Guanfacine

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Related Disorders

    phase 2 small molecule completed

    1 trial

  42. Guanfacine

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Use Disorders

    phase 2 small molecule completed

    1 trial

  43. Guanfacine

    BRIGHT MINDS BIOSCIENCES INC.

    Smoking Cessation

    phase 2 small molecule completed

    1 trial

  44. HEART to HAART

    BRIGHT MINDS BIOSCIENCES INC.

    HIV

    phase 2 other completed

    1 trial

  45. Heart Rate Variability Biofeedback

    BRIGHT MINDS BIOSCIENCES INC.

    Tobacco Smoking

    phase 2 mab completed

    1 trial

  46. Heroin Dependence

    BRIGHT MINDS BIOSCIENCES INC.

    Heroin Dependence

    phase 2 small molecule terminated

    1 trial

  47. High-dose donepezil

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Use Disorders

    phase 2 small molecule completed

    1 trial

  48. Hydroxycarbamid

    BRIGHT MINDS BIOSCIENCES INC.

    Central Retinal Vein Occlusion, Non-Ischemic

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does BRIGHT MINDS BIOSCIENCES have?

1,063 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.